News
Gilead Sciences' chief medical officer Merdad Parsey

Merdad Parsey will leave Gilead next year

Gilead Sciences' chief medical officer, Merdad Parsey, will leave the company in early 2025, becoming the latest in a series of high-profile departures involving senior R&D figures at t

News
House Oversight Committee chair James Comer (r)

PBMs will face House committee grilling next week

The House Committee on Oversight and Accountability will quiz leaders of pharmacy benefit managers (PBMs) at a hearing next week, amid scrutiny of the sector's role in rising healthcare cos

Sales & Marketing

Digital

Market Access

Newsletters and Deep Dive
digital magazine

Oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

Patients

R&D

Partner Content

R&D
FT Global Pharma & Biotech Summit 2024 banner
Partner Content

FT Global Pharma & Biotech Summit 2024

The Global Pharma and Biotech Summit is the essential annual event for you to stay on top of the latest trends and innovations in life sciences.

R&D
9th CDD For Biologics Summit 2024 banner
Partner Content

9th CDD For Biologics Summit 2024

Integrate Computational Biology, Generative AI & Machine Learning to Revolutionize Biologics Drug Discovery & Development